Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results
Date:11/6/2013

an alternative to GAAP measures. 

"We are pleased with the overall momentum of the business and are delighted to deliver what we consider to be a strong third quarter of record revenues in addition to significant non-GAAP earnings per share growth," said Adrian Adams, Chief Executive Officer and President of Auxilium.  "The recent in-licensing of  STENDRA™, a first line oral therapy for erectile dysfunction, further  reflects a  successful execution of our corporate development and licensing strategy which remains focused on diversifying and strengthening our product portfolio. This, together with the potential opportunity for XIAFLEX in Peyronie's disease, if approved by the FDA, and measured progress in research and development with the initiation of a Phase 2a study in cellulite and pending initiation of a Phase 2b study in frozen shoulder later this year positions us well, we believe, to drive increased shareholder value over time."

Third Quarter 2013 and Recent Highlights:

  • On October 23, 2013, Auxilium announced the first cohort of patients has been dosed in its Phase 2a study of collagenase clostridium histolyticum (or "CCH") for the treatment of edematous fibrosclerotic panniculopathy ("EFP), commonly known as cellulite, following positive results observed in earlier open-label studies.
  • On October 11, 2013, Auxilium announced the signing of an agreement with VIVUS, Inc. (Nasdaq: VVUS) providing Auxilium with the exclusive right to market VIVUS's product, STENDRA (avanafil), in the United States and Canada.  STENDRA is an oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of erectile dysfunction. 
  • In September, Auxilium announced it entered into an Incremental Assumption Agreement ("Incremental Agreement") with Morgan Stanley Senior Funding, Inc. ("MSSF") unde
    '/>"/>

  • SOURCE Auxilium Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
    2. Auxilium Pharmaceuticals to Announce First Quarter 2012 Results and Conduct Conference Call on Thursday, May 10, 2012
    3. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
    4. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
    5. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
    6. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
    7. Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2012 Financial Results
    8. Auxilium Pharmaceuticals to Announce Third Quarter 2012 Results and Conduct Conference Call on Wednesday, November 7, 2012
    9. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
    10. Auxilium Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes Due 2018
    11. Auxilium Pharmaceuticals, Inc. Announces Pricing of $325.0 Million of 1.50% Convertible Senior Notes Due 2018
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... , July 11, 2014 ... at 4,396.20, down 0.52%, the Dow Jones Industrial Average finished ... closed at 1,964.68, down 0.41%. The losses were broad based ... negative. The S&P 500 Health Care Sector Index ended the ... 2.75% in the last one month. Investor-Edge has initiated coverage ...
    (Date:7/11/2014)... , July 11, 2014 Neurelis, Inc. ... ("Biotie") to end the option held by Biotie to ... further development of NRL-1 (intranasal diazepam) for pediatric and ... Over the past year, Biotie has advanced the ... preparation for the pivotal clinical work required for NDA ...
    (Date:7/10/2014)... Integrated Silicon Solution, Inc. (Nasdaq: ... IC solutions, today announced that it will host its ... 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) to ... third quarter ended June 30, 2014. To ... 6:50 a.m. Pacific time on July 24, 2014.  The ...
    Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
    ... Health, Inc. (Nasdaq: GHDX ) today announced plans ... improving the quality of diagnosis, communication and support for millions ... genetic conditions.   The subsidiary is expected to be established by ... 2013.  The new venture will be led by Randy Scott, ...
    ... 2012 TeDan Surgical Innovations , industry leader ... Phantom Series MIS Anterior Hip Retractor System . ... adjustable surgical arms with attachable retractors, enabling surgeons to ... a surgical assistant. Dr. Lawrence Menendez ...
    Cached Medicine Technology:Genomic Health Announces Formation of New Genetics Subsidiary 2Genomic Health Announces Formation of New Genetics Subsidiary 3Genomic Health Announces Formation of New Genetics Subsidiary 4New Minimally Invasive Hip Retractor Revolutionizes Anterior Hip Replacement Procedures 2
    (Date:7/12/2014)... "The second toes cross over the big toes ... shoes," said an inventor from East Hartford, Conn. This gave ... happening. , He then created a prototype of the Comfort ... and big toes from overlapping. This avoids discomfort and pain, ... easy to use, it's ideal for people with foot problems, ...
    (Date:7/12/2014)... 12, 2014 Using and carrying around ... two inventors from Ashland, Va., decided that there needed ... inspired us to conceive of our design," he said. ... KIDNEY KOVER, which provides an inconspicuous way to use ... as well as promotes comfort and peace of mind. ...
    (Date:7/12/2014)... July 12, 2014 For those who are ... can readily absorb the nutrients in food. The enzymes literally ... are small enough to be absorbed by human bodies. According ... lack of enzymes in regular food is the cause of ... that was started by Michelle DelPresto, a mother of 3 ...
    (Date:7/12/2014)... Doylestown Hospital recently conducted an interview ... health questions. Paddock tackles topics including main men's ... live longer than men, and testosterone replacement therapy, among ... featured on Doylestown Hospital’s website, Dr. Brad Paddock ... age. If you notice pain, bulging, or asymmetry in ...
    (Date:7/12/2014)... 2014 Dubai is buzzing with the ... heading to the UAE. The National Basketball Association’s ... in the UAE from 28-31 October to lead the ... diabetes awareness. The event is being organized by Maven ... management company based in Dubai. The announcement was made ...
    Breaking Medicine News(10 mins):Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3
    ... ... customers with an advanced BlackBerry® smartphone paging solution. Onset METAMessage® enables Indiana Paging Network ... RIMM) via their current pager number and eliminate the need to carry two devices. ... (PRWEB) April ...
    ... the number of preventable patient injuries in California hospitals ... drop in malpractice claims against physicians, according to a ... Researchers studied both medical malpractice claims and adverse events ... that changes in the frequency of adverse events were ...
    ... Experimental treatment offers hope against cancer that returns after castration ... that a new hormone treatment could be a weapon for ... that,s resistant to surgical removal of the testicles. , ... new drug treatments have been completed, however. At this point, ...
    ... ... comprehensive and successful anti-obesity program, First Lady Michelle Obama’s “Let’s Move” campaign must ... , ... (Vocus) April 14, 2010 -- To be a truly comprehensive and successful ...
    ... , ... the impact of statins on the progression of multiple sclerosis found a lower incidence of ... disease as compared to a placebo. , ... (Vocus) April 14, 2010 -- A UCSF-led study examining the impact of statins ...
    ... unsavory-sounding name "corn smut" wields different weapons from its ... it infects. The discovery by Stanford researchers marks the ... pathogen. The finding upends conventional notions of how ... approaches to fighting disease not only in plants but ...
    Cached Medicine News:Health News:Indiana Paging Network and Onset Technology Partner to Deliver Paging Messages to Blackberry Smartphones 2Health News:Indiana Paging Network and Onset Technology Partner to Deliver Paging Messages to Blackberry Smartphones 3Health News:Better patient safety linked to fewer medical malpractice claims in California 2Health News:Hormone Therapy May Fight Resistant Prostate Cancer 2Health News:Childhood Obesity Interventions Must Begin Early, UCSF Experts Say 2Health News:Childhood Obesity Interventions Must Begin Early, UCSF Experts Say 3Health News:Childhood Obesity Interventions Must Begin Early, UCSF Experts Say 4Health News:Statins May Slow Progression of Multiple Sclerosis, New Study Finds 2Health News:Statins May Slow Progression of Multiple Sclerosis, New Study Finds 3Health News:Statins May Slow Progression of Multiple Sclerosis, New Study Finds 4Health News:Plant pathogen genetically tailors attacks to each part of host, say Stanford researchers 2Health News:Plant pathogen genetically tailors attacks to each part of host, say Stanford researchers 3Health News:Plant pathogen genetically tailors attacks to each part of host, say Stanford researchers 4
    Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
    Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
    Testing for Strabismus (ocular misalignment) just became easier. By simply placing the StrabismoScope over the patient's eye, the examiner is able to observe the occluded eye directly, but the patien...
    The Welch Allyn 125 BIO is designed to achieve precise binocular viewing and stereopsis easier than ever before. Its observation paths can be adjusted from 48 mm to 74 mm to handle the widest and nar...
    Medicine Products: